Is OTLK or PBYI more undervalued in 2026?

CirclFi compares Outlook Therapeutics, Inc. (OTLK) and Puma Biotechnology Inc (PBYI) using 13 institutional-grade valuation models. OTLK has a Quality of Company score of 3.7/10 while PBYI scores 8.4/10.

Which is a better buy — OTLK or PBYI?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do OTLK and PBYI valuations compare?

OTLK at $0.74 and PBYI at $7.24 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

OTLK vs PBYI Valuation Comparison 2026 — Intrinsic Value Analysis

OTLK

Biotechnology

Outlook Therapeutics, Inc.

Quality

3.7

out of 10

Value Trap

LOW

Price

$0.74

Last close

Models

9/13

Active

PBYI

Biotechnology

Puma Biotechnology Inc

Quality

8.4

out of 10

Value Trap

SAFE

Price

$7.24

Last close

Models

12/13

Active

Model-by-Model Comparison

Model	Type	OTLK Fair Value	OTLK Upside	PBYI Fair Value	PBYI Upside
Bayesian DCF	Intrinsic	$0.13	-83.0%	$6.50	-10.2%
Earnings Power Value	Intrinsic	$0.17	-35.9%	$4.28	-40.8%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%
RCMH-DCF	Intrinsic	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for OTLK vs PBYI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

OTLK vs PBYI — Which Stock Is More Undervalued?

PBYI scores higher with a 8.4/10 quality rating vs OTLK's 3.7/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Outlook Therapeutics, Inc. (OTLK) and Puma Biotechnology Inc (PBYI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

OTLK currently trades at $0.74 with a QOC of 3.7/10, while PBYI trades at $7.24 with a QOC of 8.4/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).